|Bid||64.00 x 203800|
|Ask||66.00 x 10000|
|Day's range||65.62 - 66.24|
|52-week range||56.55 - 71.28|
|PE ratio (TTM)||16.58|
|Earnings date||26 Jul 2018|
|Forward dividend & yield||1.18 (1.80%)|
|1y target est||69.16|
Representatives from the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE), alongside prominent members of the Global epilepsy community, are meeting this week to encourage World Health Assembly (WHA) members and the World Health Organization (WHO) to continue to recognize epilepsy as a global health priority in countries around the world. Coinciding with the 71st World Health Assembly, advocates will focus on progressing the milestone 2015 WHO Resolution on epilepsy to encourage countries to prioritise epilepsy at national levels, including promoting awareness, eliminating stigma of the disease, expanding research capacity, improving monitoring and surveillance, and expanding access to care.
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the company's newest anti-epileptic drug (AED) BRIVIACT® (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial onset (focal) seizures in patients age four years and older. This approval provides clinicians with the convenient option to prescribe BRIVIACT to their pediatric patients as a tablet or oral solution, providing flexible administration options which are important considerations when treating children.
Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018. Nasal administration could provide significant value to patients who currently have limited treatment options.
UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. Element Genomics' proven technologies and expertise will enhance UCB's scientific research platform enabling the company to continue to enrich its pipeline, in particular strengthening target discovery and characterization in disease relevant systems.
*** Unofficial English translation - For convenience purposes only *** UCB SA/NV - Public Limited Liability Company Allée de la Recherche 60, 1070 Brussels Enterprise nr. 0403.053.608 (RLE Brussels) ...
Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes